Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
2.24B
Market cap2.24B
Price-Earnings ratio
-7.66
Price-Earnings ratio-7.66
Dividend yield
Dividend yield
Average volume
3.14M
Average volume3.14M
High today
$22.34
High today$22.34
Low today
$21.22
Low today$21.22
Open price
$22.14
Open price$22.14
Volume
2.31M
Volume2.31M
52 Week high
$120.05
52 Week high$120.05
52 Week low
$10.42
52 Week low$10.42

Stock Snapshot

Sarepta Therapeutics(SRPT) stock is priced at $21.30, giving the company a market capitalization of 2.24B. It carries a P/E multiple of -7.66.

On 2026-01-28, Sarepta Therapeutics(SRPT) stock traded between a low of $21.22 and a high of $22.34. Shares are currently priced at $21.30, which is +0.4% above the low and -4.7% below the high.

Sarepta Therapeutics(SRPT) shares are trading with a volume of 2.31M, against a daily average of 3.14M.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $120.05 and a 52-week low of $10.42.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $120.05 and a 52-week low of $10.42.

SRPT News

TipRanks 1d
Sarepta assumed with an Equal Weight at Barclays

Barclays assumed coverage of Sarepta (SRPT) with an Equal Weight rating and $20 price target Barclays initiated coverage of 12 biotech stocks and assumed covera...

TipRanks 1d
Sarepta price target raised to $22 from $15 at Baird

Baird raised the firm’s price target on Sarepta (SRPT) to $22 from $15 and keeps a Neutral rating on the shares. The firm updated its model following the releas...

TipRanks 1d
Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating

Citi analyst Yigal Nochomovitz has assigned their bearish stance on SRPT stock, giving a Sell rating today. Claim 50% Off TipRanks Premium Unlock hedge fund-lev...

Analyst ratings

54%

of 26 ratings
Buy
26.9%
Hold
53.8%
Sell
19.2%

More SRPT News

Simply Wall St 2d
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks

Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy. The r...

Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks
Benzinga 2d
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones gaining over 100 points on Monday. Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) rose sharply during Monday's se...

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
Benzinga 2d
Sarepta Says Elevidys Slows Duchenne Progression After Three Years

Sarepta Therapeutics Inc. (NASDAQ:SRPT) on Monday released topline three-year functional results from Part 1-treated patients in the EMBARK (Study SRP-9001-301)...

Sarepta Says Elevidys Slows Duchenne Progression After Three Years
TipRanks 2d
Sarepta reports ‘positive’ topline three-year EMBARK results for Elevidys

Sarepta (SRPT) Therapeutics announced “positive” topline three-year functional results from Part 1-treated patients in EMBARK, the global, randomized placebo-co...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.